2 results
Approved WMOCompleted
The primary objective of this study is to assess the objective response rates (ORR) for two starting doses of vandetanib, 150 mg and 300 mg in patients with unresectable locally advanced or metastatic MTC having progressive or symptomatic disease.…
Approved WMOCompleted
Primary:- To evaluate the safety and tolerability of repeat doses of GSK2831781 during the Induction Phase.- To characterise the efficacy dose-response of GSK2831781 during the Induction Phase.Secondary:- To evaluate the safety and tolerability of…